Cancer-diagnostics specialist Guardant Health (NASDAQ: GH) was a standout in the biotech sector on Hump Day. Investors cheered the company’s news that one of its products made it onto a list of top innovations compiled by a familiar magazine. In response, they traded Guardant’s shares up by almost 6%, making it quite the outperformer when matched against the S&P 500 index’s 0.3% drop on the day.
That magazine was the once-influential but still widely read Time, which flagged Guardant’s Shield product as being one of its best inventions of 2024. The annual list compiled by the magazine features, in its words, “200 innovations changing how we live.”
Time selected Shield, a colorectal cancer diagnosis kit, as one of the 200. Praising Shield for making the traditionally uncomfortable screening process “as routine as getting blood drawn,” it pointed out that Guardant harnesses data analysis and artificial intelligence (AI) to produce the test’s results.
The magazine added that the influential medical publication The New England Journal of Medicine said that Shield’s detection-sensitivity rate was an impressive 83%. That makes it indisputably a fine weapon in the fight against colorectal cancer, which causes around 53,000 deaths annually in the U.S. and is one of the leading potentially fatal illnesses in the country.
In the press release trumpeting Shield’s inclusion on the list, the healthcare company’s co-CEO and co-founder AmirAli Talasaz said that he and his team “[are] honored to be a part of this prestigious list of leading innovative products that are making a dramatic difference in how we live our lives today.”
Inclusion on the list alone isn’t going to vault Guardant into the ranks of top-specialty healthcare providers, but it will undoubtedly provide a free public relations boost to Shield. This product, which only won Food and Drug Administration (FDA) approval in July, already has quite a bit of momentum and should be popular with the company’s quite focused customer base.
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
Amazon: if you invested $1,000 when we doubled down in 2010, you’d have $21,492!*
Apple: if you invested $1,000 when we doubled down in 2008, you’d have $44,204!*
Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $409,559!*
Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.
*Stock Advisor returns as of October 28, 2024
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Guardant Health. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]